Company FUSN PHAR

Equities

FUSN

CA36118A1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
21.25 ^USD	+0.05%		-0.51%	+121.12%

Apr. 16	TD Cowen Downgrades Fusion Pharmaceuticals to Hold	MT
Apr. 09	Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	CI

Business Summary

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company's lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.

Number of employees: 101

Sales per Business

USD in Million	2022	Weight	2023	Weight	Delta
Next-generation Radiopharmaceuticals 100.0 %	1	100.0 %	2	100.0 %	+41.55%

Managers

Managers	Title	Age	Since
John Valliant FOU	Founder	54	14-11-30
Mohit Rawat PSD	President	-	21-09-27
John Crowley DFI	Director of Finance/CFO	51	19-01-31
Dmitri Bobilev CTO	Chief Tech/Sci/R&D Officer	-	22-11-06
Joanne Schindler CTO	Chief Tech/Sci/R&D Officer	-	-
Eric Burak CTO	Chief Tech/Sci/R&D Officer	-	17-01-31
Christopher Leamon CTO	Chief Tech/Sci/R&D Officer	57	21-11-01
Amanda Cray IRC	Investor Relations Contact	-	-
Cara Ferreira HRO	Human Resources Officer	-	20-10-31
Maria D. Stahl LAW	General Counsel	53	20-09-28

Members of the board

Members of the board	Title	Age	Since
Pablo Cagnoni BRD	Director/Board Member	60	19-11-30
Barbara Duncan CHM	Chairman	59	20-11-01
Steven Gannon BRD	Director/Board Member	62	19-12-31
Jeremy Bender BRD	Director/Board Member	52	23-10-15
David Meek BRD	Director/Board Member	59	23-10-15
Donald Bergstrom BRD	Director/Board Member	52	21-03-31
Teresa Bitetti BRD	Director/Board Member	-	23-10-15
John Valliant FOU	Founder	54	14-11-30
Philina Lee BRD	Director/Board Member	47	21-02-10

Shareholders

Name	Equities	%	Valuation
Federated Equity Management Company of Pennsylvania 12.85 %	10,886,153	12.85 %	232 M $
Federated Global Investment Management Corp. 12.77 %	10,811,153	12.77 %	230 M $
Avidity Partners Management LP 7.675 %	6,500,328	7.675 %	139 M $
Deerfield Management Co. LP (Private Equity) 7.558 %	6,401,000	7.558 %	136 M $
Fidelity Management & Research Co. LLC 6.274 %	5,313,294	6.274 %	113 M $
Perceptive Advisors LLC 5.593 %	4,737,194	5.593 %	101 M $
HealthCap AB 4.495 %	3,807,247	4.495 %	81 M $
Johnson & Johnson Innovation - JJDC, Inc. 4.334 %	3,670,516	4.334 %	78 M $
Varian Medical Systems, Inc. 3.846 %	3,256,972	3.846 %	69 M $
OrbiMed Advisors Private Equity 3.687 %	3,122,770	3.687 %	67 M $